
Broad-Based Technical Strength Lifts Emcure Pharmaceuticals Ltd to 52-Week High of Rs 2401.5
2026-11-18 12:37:56Surging to an all-time high of Rs 2401.5 on 18 Nov 2026, Emcure Pharmaceuticals Ltd has demonstrated remarkable price momentum, outperforming its sector and the broader market despite a subdued Sensex. This milestone caps a 74.84% rally over the past year, underscoring the stock’s robust technical underpinnings and sustained upward trajectory.
Read More
Broad-Based Technical Strength Lifts Emcure Pharmaceuticals Ltd to 52-Week High of Rs 2397.5
2026-11-17 10:39:24Surging to an intraday peak of Rs 2397.5 on 17 Nov 2026, Emcure Pharmaceuticals Ltd has marked a significant milestone by reaching a fresh 52-week high. This rally, driven by a confluence of robust technical indicators and sustained price momentum, underscores the stock’s impressive outperformance against both its sector and the broader market.
Read More
Emcure Pharmaceuticals Ltd is Rated Buy by MarketsMOJO
2026-11-16 10:11:08Emcure Pharmaceuticals Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 04 Nov 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 November 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.
Read More
Broad-Based Technical Strength Lifts Emcure Pharmaceuticals Ltd to 52-Week High of Rs 2394.55
2026-11-13 11:12:00Surging past its previous peaks, Emcure Pharmaceuticals Ltd reached a fresh 52-week high of Rs 2394.55 on 13 Nov 2026, marking a remarkable 72.9% gain over the past year. This milestone reflects a powerful confluence of technical momentum and sustained price strength, even as the broader market trades cautiously.
Read MoreEmcure Pharmaceuticals Surges 18.58%: 5 Key Drivers Behind This Week’s Rally
2026-11-07 11:00:10Key Events This Week 2 Nov: Stock opens at Rs.1,882.50, Sensex at 34,786.71 3 Nov: Intraday high surge of 7.92%, closing at Rs.1,982.55 4 Nov: New 52-week and all-time high at Rs.2,180.80; upper circuit hit 5 Nov: Further 52-week high at Rs.2,191; mojo rating upgraded to Buy 6 Nov: Slight correction to Rs.2,215.10, closing the week strong Week OpenRs.1,868.1...
Read More
Broad-Based Technical Strength Lifts Emcure Pharmaceuticals Ltd to 52-Week High of Rs 2191
2026-11-05 10:19:07Surging to a fresh 52-week high of Rs 2,191 on 5 Nov 2026, Emcure Pharmaceuticals Ltd has demonstrated remarkable price momentum, outpacing the broader market with a 64.43% gain over the past year against the Sensex’s decline of 5.57%. This milestone caps a five-day winning streak that has propelled the stock 17.21% higher, reflecting a strong alignment of technical indicators and sustained buying interest.
Read More
Emcure Pharmaceuticals Upgraded to Buy on Strong Technical and Financial Performance
2026-11-05 08:45:00Emcure Pharmaceuticals Ltd has seen its investment rating upgraded from Hold to Buy, reflecting significant improvements across technical indicators, valuation metrics, financial trends, and overall quality. The upgrade, effective from 4 November 2026, comes amid a strong market performance and robust quarterly results, positioning the small-cap pharmaceutical firm favourably against its peers and broader market benchmarks.
Read More
Emcure Pharmaceuticals Ltd: Valuation Shift Signals Elevated Price Attractiveness Amid Sector Comparisons
2026-11-05 08:04:10Emcure Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to a very expensive rating, reflecting a significant change in price attractiveness. This revaluation comes amid robust stock performance and improving fundamentals, positioning the small-cap pharmaceutical player favourably against its peers and historical benchmarks.
Read More
Emcure Pharmaceuticals Ltd Surges 7.17% to Day's High of Rs 2180.8 — Outperforms Sector by 6.78 Percentage Points
2026-11-04 10:23:18The Sensex rose 0.28% on 04 Nov 2026, yet Emcure Pharmaceuticals Ltd outpaced the broader market with a 7.17% gain, touching a new 52-week and all-time high of Rs 2180.8. This 6.78 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers highlights a distinctly stock-specific rally rather than a market-wide lift.
Read MoreIntimation Of Cancellation Of Schedule Of Analyst/ Investor Meeting(S) Scheduled On November 16 2026
14-Nov-2026 | Source : BSEAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
06-Nov-2026 | Source : BSEIntimation of schedule of Analyst/Investor Meeting dated Monday November 16 2026
Announcement under Regulation 30 (LODR)-Investor Presentation
06-Nov-2026 | Source : BSEIntimation of schedule of Analyst/Investor Meeting on Monday November 16 2026
Corporate Actions
No Upcoming Board Meetings
Emcure Pharmaceuticals Ltd has declared 36% dividend, ex-date: 04 Sep 26
No Splits history available
No Bonus history available
No Rights history available